| Indication | Myeloproliferative neoplasms |
| Mechanism of Action | Biparatopic antibody |
| Company | Eli Lilly |
| Category | Corporate & Strategic |
| Sub Category | Acquisition Announced |
| Therapeutic Area | Hematology |
| Deal Value | $1.5 billion |
| Deal Type | Acquisition |
| Payment Structure | Upfront payment and milestone payouts |
| Target Gene | CALR |
| Lilly's Acquisitions This Year | 15 |
| Lilly's Total Spend This Year | Over $30 billion |
| Target Conditions | Myelofibrosis, Essential thrombocythemia |
| Founding Investors | J.P. Morgan Asset Management, Westlake BioPartners, Avoro Ventures |
Eli Lilly Acquires Calytrix Bio for Up to $1.5 Billion
Eli Lilly has acquired Calytrix Bio, a Wellesley, Massachusetts-based startup, for up to $1.5 billion, comprising an upfront payment and subsequent payouts tied to clinical and regulatory milestones. This acquisition marks Lilly's 15th company purchase this year, bringing its total spend to over $30 billion. Calytrix Bio specializes in developing precision therapies for rare blood cancers known as myeloproliferative neoplasms, specifically targeting diseases like myelofibrosis and essential thrombocythemia. Their lead asset is a novel biparatopic antibody designed to precisely target cell-surface proteins driven by CALR gene mutations, aiming to change disease trajectory rather than just manage symptoms.
- Eli Lilly is acquiring Calytrix Bio for a total consideration of up to $1.5 billion. This deal includes an undisclosed upfront payment along with subsequent payouts contingent upon achieving specific clinical and regulatory milestones. This financial structure underscores the potential value Lilly sees in Calytrix's innovative pipeline for rare blood disorders.
- Calytrix Bio is focused on developing a unique 'biparatopic' antibody designed to treat myeloproliferative neoplasms, including myelofibrosis and essential thrombocythemia. This therapy specifically targets a cell-surface protein that emerges due to mutations in the CALR gene, binding to two separate sites on the same protein to precisely address disease-causing mutations while sparing healthy tissue.
- This acquisition is part of Eli Lilly's aggressive M&A strategy, marking its 15th company acquisition this year. With this purchase, Lilly's total spending on company acquisitions in 2026 surpasses $30 billion, positioning it as the biotech sector's most prolific dealmaker compared to other major pharmaceutical companies like GSK, Gilead Sciences, and Novartis.
Lilly's Strategic Expansion in the Evolving MPN Landscape
Janus kinase inhibitors (JAKis) ruxolitinib, fedratinib, and pacritinib are the current standard of care in symptomatic myelofibrosis (MF), with four JAKi approved for intermediate or high-risk MF in the US. Regulatory approval of the first JAK1/2 inhibitor, ruxolitinib, in 2011 transformed management by controlling splenomegaly and constitutional symptoms and prolonging survival. Fedratinib, the second approved JAKi, is preferred in the second-line setting, while pacritinib and momelotinib are potent ACVR1 inhibitors resulting in significant anemia benefits, with pacritinib receiving regulatory approval for severely thrombocytopenic MF patients and transfusion independence achieved with momelotinib in severely anemic patients. Durability remains limited, with ∼50% of patients discontinue within 1 year due to loss of efficacy or intolerance, approximately half of treated patients discontinue ruxolitinib treatment within 3 years and up to approximately 75% within 5 years, with poor outcomes after discontinuation where median survival in several series is approximately 12-14 months.
Efficacy beyond JAKi monotherapy has centered on rational combinations and non-JAK small molecules evaluated against spleen volume reduction (SVR35) and total symptom score reduction (TSS50) at week 24. Pelabresib (CPI-0610), an oral, small-molecule BET1,2 inhibitor (BETi), in combination with ruxolitinib showed improvements in SVR35 and TSS50 from baseline in the phase 2 MANIFEST study (NCT02158858) in JAKi treatment-naive patients with MF, and an unanchored matching-adjusted indirect comparison of arm 3 of MANIFEST with COMFORT-I and COMFORT-II (ruxolitinib), SIMPLIFY-1 (ruxolitinib and momelotinib), and JAKARTA (fedratinib) showed response rate ratios >1 for pelabresib with ruxolitinib vs all comparators for SVR35 and TSS50 at week 24, with improvements in TSS observed as early as week 12. In relapsed or refractory MF to JAKis, imetelstat 9.4 mg/kg intravenous once every 3 weeks in study NCT02426086 produced spleen and symptom response rates of 10.2% and 32.2% at week 24 versus 0% and 6.3% in the 4.7 mg/kg arm, with median OS of 29.9 months and bone marrow fibrosis improvement in 40.5% and variant allele frequency reduction of driver mutations in 42.1% of evaluable patients. Bomedemstat, an irreversible inhibitor of lysine-specific demethylase 1 (LSD1), was evaluated in 89 participants with MF refractory or resistant to, inadequately controlled by, or intolerant of approved therapies in study NCT03136185, where 87 participants (97%) experienced ≥1 any-cause adverse event, most commonly thrombocytopenia (48%) and dysgeusia (36%), and of 35 participants with spleen volume data at week 24, 23 (66%) had a reduction in spleen volume and 9 (26%) had a reduction of ≥20%.
In BCR/ABL-negative myeloproliferative neoplasms driven by JAK2, CALR, and MPL mutations, recombinant interferon alfa has advanced to regulatory approval in polycythemia vera (PV). Ropeginterferon alfa-2b received approval for PV by the European Medicines Agency and the US Food and Drug Administration in 2019 and 2021, respectively, supported by PROUD-PV and CONTINUATION-PV studies, with long-term therapy able to selectively deplete mutant JAK2-harboring hematopoietic stem cells and produce partial or complete reduction of the mutant JAK2 allele burden. A systematic review of 37 reports including data from 1794 patients with PV and essential thrombocythemia reported a pooled overall hematological response rate of 86% and pooled overall molecular response rate of 48% after interferon therapy, with overall incidence of 0.42/100 person-years for thrombosis, 0.21/100 person-years for myelofibrotic transformation, and 0.08/100 person-years for leukemic transformation. Trial design is shifting toward disease modification endpoints encompassing more than SVR35 and TSS50 at 24 weeks, including bone marrow fibrosis change, variant allele frequency monitoring, anemia response and transfusion independence, event-free survival (EFS), and overall survival (OS), with OS set as the primary endpoint for imetelstat in the second line setting and investigational mechanisms spanning PIM kinase inhibitors (TP-3654), nuclear export inhibition (selinexor), MDM2 antagonism (navtemadlin/KRT-232), mutant CALR-directed immunotherapies, activin receptor ligand traps (elritercept), PI3K signaling (parsaclisib), and apoptosis regulation (navitoclax).
Why Current MPN Therapies Fall Short for Patients
Current approaches for myeloproliferative neoplasms, centered on JAK inhibitors, improve splenomegaly, symptom burden and quality of life but have not established an ability to modify disease in terms of resolution of bone marrow fibrosis or molecular remissions. Allogeneic hematopoietic cell transplantation remains the only curative therapy, yet its use is constrained by age, comorbidities, and treatment-related toxicity.
Limited disease-modifying activity and persistent clonal evolution: Despite spleen volume and symptom benefit, there is limited impact to induce complete haematological remission with normalisation of blood counts, reduce the mutant allele burden or reverse bone marrow fibrosis. Clonal evolution has been observed on ruxolitinib therapy and transformation to acute leukaemia can still occur, while durability of responses, impact on survival and leukemic transformation remain unresolved.
Myelosuppression, cytopenias and treatment-related toxicities: Optimizing dosing to secure clinically relevant and durable benefits while minimizing myelosuppression is a major challenge, with resistance, adverse effects such as cytopenias and infectious complications, and anemia that is common in MF and initially worsened by ruxolitinib. For transplantation, complications such as graft-versus-host disease remain the major barrier to greater success, with delayed neutrophil and platelet engraftment associated with marrow fibrosis, splenomegaly and conditioning regimen, and risk of early mortality and nonrelapse mortality.
Restricted eligibility and unresolved sequencing and combination strategy: The only curative option can result in durable donor engraftment and regression of myelofibrosis in approximately 50% of eligible patients, but the median age at presentation is 65 years and many patients have serious comorbidities, so the vast majority of patients are excluded and the modality is generally restricted to younger patients with intermediate-to high-risk disease. Toxicity profiles and optimal sequencing remain areas of active investigation, including pairing ruxolitinib with investigational agents, managing loss of response to JAK inhibitors, and biomarker-driven patient selection.
Unlocking CALR Mutations: Calytrix's Biparatopic Antibody
Myeloproliferative neoplasms (MPNs) are clonal disorders arising in hematopoietic stem or progenitor cells characterized by overproduction of mature blood cells, with driver mutations in genes associated with the JAK-STAT pathway including JAK2 V617F, JAK2 exon 12 mutations and mutations in MPL, CALR, and CSF3R. The most prevalent mutation, JAK2 V617F, is found in 95% of polycythemia vera patients and 50% of patients suffering from essential thrombocythemia and primary myelofibrosis, while CALR and MPL mutations are associated only with essential thrombocythemia and myelofibrosis. All the mutated proteins lead to pathologic and persistent JAK2-STAT5 activation, with MPLW515L identified in 9% (4/45) of JAK2V617F-negative myelofibrosis conferring cytokine-independent growth and resulting in constitutive phosphorylation of JAK2, STAT3, STAT5, AKT, and ERK. JAK-mediated signaling critically relies on STAT transcription factors, and on activation of the MAPK and PI3K/Akt signaling axes, with JAK2(V617F) mutation constitutively activating JAK2, pErk and PI3K-Akt signaling.
Disease initiation and progression reflect cooperating somatic lesions, germline predisposition, and clonal evolution. A set of epigenetic mutations can co-exist with phenotypic driver mutations in 35%-40% of MPNs, involving epigenetic regulators (e.g. ASXL1, DNMT3A, EZH2, IDH1, IDH2, SUZ12, TET2, UTX), components of the spliceosome (e.g. SF3B1, SRSF2), transcription factors (e.g. CEBPA, ETV6, RUNX1), tumor suppressors (e.g. TP53), and signaling proteins (e.g. CBL, FLT3, JAK2, RAS). Germline variants predispose to both JAK2 V617F clonal hematopoiesis and MPNs, most strongly the JAK2 46/1 haplotype (GGCC), with additional associations in TERT (rs7705526: OR = 1.8), SH2B3, TET2, CHEK2, ATM, PINT, GFI1B, MECOM, DDX41 and RUNX1. In 46 paired chronic phase and blastic phase samples, median time from chronic phase to blastic phase was 6.9 (range 0.3-27.8) years, driver mutation frequency was 98% (JAK2-V617F 67%, CALR 28%, MPL 2%) in chronic phase and decreased to 78% in blastic phase due to JAK2-V617F loss, with all CALR mutations preserved, while total mutation numbers increased (median 2 vs. 3), spliceosome mutations rose from 26% to 39%, transcription-related mutations from 13% to 33%, and RUNX1, TP53 and most signaling gene mutations emerged predominantly in blastic phase.
Cellular remodeling of the bone marrow niche and chronic inflammatory signaling drive fibrotic progression and clinical features including bone marrow fibrosis, splenomegaly, vascular niche remodeling, thrombosis and secondary leukemic transformation. In primary myelofibrosis, megakaryocyte dysplasia/hyperplasia determines release of inflammatory cytokines that stimulate stromal cells and induce fibrosis, with increased proplatelet density, extensive pseudopodial proplatelet formation, and increased pErk, pAkt and p70S6k expression in megakaryocytes. Most collagen-expressing myofibroblasts were derived from leptin-receptor-positive mesenchymal cells with reduced expression of hematopoietic niche factors and increased expression of fibrogenic factors, while pericytes and Sox10 glial cells expanded drastically and chemical or genetic ablation of bone marrow glial cells ameliorated fibrosis. Monocytes are a major source of proinflammatory cytokines and monocyte-derived fibrocytes play a pivotal role in myelofibrosis, with elevated CD38 expression in Ly6chigh monocytes and CD14+ monocytes from myelofibrosis patients, pronounced lower NAD+ levels, and increased CD45+CollagenI+ fibrocytes mainly derived from Ly6chigh monocytes. Mutations activate the JAK-STAT pathway and disrupt NF-κB signaling, leading to a chronic inflammatory state caused by pro-inflammatory cytokines and reactive oxygen species, with higher ROS and lower total antioxidant capacity, progressive lymphopenia, T and B cell exhaustion, Natural Killer cell maturation arrest, and accumulation of myeloid-derived suppressor cells.
Frequently Asked Questions
References
- [1] Abruzzese E, Trawinska MM et al.. The Path Forward in MF: Small Molecules in the Limelight. Cancers. 2026 Apr 25. 42122166
- [2] Benjamin J, Chhabra S et al.. Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2014 Jun. 24607552
- [3] Roskoski R Jr. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. Pharmacological research. 2016 Sep. 27473820
- [4] Sugimoto H, Sawa N et al.. Focal Segmental Glomerulosclerosis Associated with Essential Thrombocythemia. Internal medicine (Tokyo, Japan). 2023 Jun 15. 36288989
- [5] Nguyen HM, Gotlib J. Insights into the molecular genetics of myeloproliferative neoplasms. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2012. 24451773
- [6] Bose P, Verstovsek S. Myelofibrosis: an update on drug therapy in 2016. Expert opinion on pharmacotherapy. 2016 Dec. 27774820
- [7] Guo BB, Linden MD et al.. Platelets in myeloproliferative neoplasms have a distinct transcript signature in the presence of marrow fibrosis. British journal of haematology. 2020 Jan. 31426129
- [8] Abu-Zeinah G, Hobbs GS et al.. Molecular Response, Event-Free Survival, and Treatment-Free Remission in Myeloproliferative Neoplasms: Update and Review with Insights from MPN Asia 2026. Current hematologic malignancy reports. 2026 Sep 18. 42758401
- [9] Bruedigam C, Porter AH et al.. Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia. Nature cancer. 2024 Jan. 37904045
- [10] Greenfield G, McPherson S et al.. The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms. Journal of translational medicine. 2018 Dec 17. 30558676
- [11] Ballen KK, Shrestha S et al.. Outcome of transplantation for myelofibrosis. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2010 Mar. 19879949
- [12] Gill H, Leung GMK et al.. Evolving landscape of JAK inhibition in myelofibrosis: monotherapy and combinations. Hematology. American Society of Hematology. Education Program. 2023 Dec 8. 38066870
- [13] Masarova L, Chifotides HT. How I individualize selection of JAK inhibitors for patients with myelofibrosis. Blood. 2025 Apr 17. 39357058
- [14] Pikman Y, Lee BH et al.. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS medicine. 2006 Jul. 16834459
- [15] Jungius S, Adam FC et al.. Characterization of engraftment dynamics in myelofibrosis after allogeneic hematopoietic cell transplantation including novel conditioning schemes. Frontiers in oncology. 2023. 37637037
- [16] Wang SJ, Yu XR et al.. [Construction of a Mouse Model for Myeloproliferative Neoplasms and an Evaluation System]. Zhongguo shi yan xue ye xue za zhi. 2023 Aug. 37551485
- [17] Gill H, Yacoub A et al.. The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study. Blood advances. 2026 Jul 14. 42054549
- [18] Chifotides HT, Bose P et al.. SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis. Clinical lymphoma, myeloma & leukemia. 2022 Apr. 34840087
- [19] Aruch D, Mascarenhas J. Contemporary approach to essential thrombocythemia and polycythemia vera. Current opinion in hematology. 2016 Mar. 26717193
- [20] Olschok K, Altenburg B et al.. The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling. Frontiers in oncology. 2023. 37941547
Contact Us
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
For General Inquiry
info@pienomial.com













